CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 301 enrolled
Drug / intervention
13vPnCbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03548337
NCT03548337Phase 4Completed
CompareCT.gov

A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13- VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS WHEN GIVEN WITH ROUTINE PEDIATRIC VACCINES IN HEALTHY INFANTS IN INDIA

Pfizer·interventional·Posted Jun 7, 2018·Updated Sep 30, 2020

In Brief

A Phase 4 clinical trial evaluating 13vPnC for Vaccines. Completed, enrolled 301 participants across 7 sites.

Detailed Summary

A Phase 4 Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccines
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJun 7, 2018
Enrollment StartMay 31, 2018
Primary CompletionDec 20, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.1 years ago

Interventions

13vPnCbiological

13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative